The age of onset and severity of symptoms can vary greatly between patients diagnosed with SMA, primarily due to the compensatory capacity of alternative genes in mitigating the loss of functional proteins translated from SMN1. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.